Literature DB >> 24428942

Visual acuity thresholds associated with activity limitations in the elderly. The Pathologies Oculaires Liées à l'Age study.

Vincent Daien1, Karine Peres, Max Villain, Alain Colvez, Isabelle Carriere, Cécile Delcourt.   

Abstract

PURPOSE: Activity limitations, which induce loss of autonomy in the elderly, are a major public health problem. We investigated the associations between objectively determined visual impairments and activity limitations and assessed the visual acuity thresholds associated with these restrictions.
METHODS: The study sample consisted of 1887 people aged 63 years and over from a population-based cohort. Moderate to severe visual impairment was defined as presenting visual acuity lower than 20/70, according to the World Health Organization (WHO) definition. In addition, we studied mild visual impairment, defined as visual acuity [20/70-20/40]. Multivariate logistic regressions were used to estimate the associations between vision and instrumental activities of daily living (IADL) limitations. Using receiver-operating characteristic (ROC) curves, we identified visual acuity thresholds that maximized the Youden index ([sensitivity + specificity]-1) for predicting IADL limitations.
RESULTS: After adjustment for potential confounders, moderate to severe visual impairment and mild visual impairment were strongly associated with IADL limitations (odds ratio [OR] = 3.49; 95% confidence interval [CI] = 1.93, 6.32 and OR = 1.77; 95% CI = 1.07, 2.91, respectively). Visual acuity was a strong predictor of IADL limitations, with an area under the ROC curve of 0.72 (95% CI = 0.68, 0.76). The best discrimination between subjects with or without IADL limitations (global, physical and cognitive) was obtained for visual acuities around 20/40-20/50.
CONCLUSION: This study confirms major increased risk for IADL limitations in subjects with moderate to severe visual impairment. In addition, it suggests that milder visual impairments (in particular below 20/40) may also be related to an increased risk for IADL limitations and should be considered for early medical intervention, before the decline of the subject autonomy.
© 2014 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  activities of daily living; autonomy; elderly, public health; visual acuity threshold

Mesh:

Year:  2014        PMID: 24428942     DOI: 10.1111/aos.12335

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  11 in total

1.  Seven-year incidence of uncorrected refractive error among an elderly Chinese population in Shihpai, Taiwan: The Shihpai Eye Study.

Authors:  T-M Kuang; S-Y Tsai; C J-L Liu; Y-C Ko; S-M Lee; P Chou
Journal:  Eye (Lond)       Date:  2016-01-22       Impact factor: 3.775

2.  Poorer Visual Acuity Is Associated with Declines in Cognitive Performance Across Multiple Cognitive Domains: The Maine-Syracuse Longitudinal Study.

Authors:  Peter J Dearborn; Merrill F Elias; Kevin J Sullivan; Cara E Sullivan; Michael A Robbins
Journal:  J Int Neuropsychol Soc       Date:  2018-06-21       Impact factor: 2.892

3.  Visual Impairment Screening at the Geriatric Frailty Clinic for Assessment of Frailty and Prevention of Disability at the Gérontopôle.

Authors:  V Soler; S Sourdet; L Balardy; G Abellan van Kan; D Brechemier; M E Rougé-Bugat; N Tavassoli; M Cassagne; F Malecaze; F Nourhashémi; B Vellas
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

4.  Ophthalmic epidemiology in Europe: the "European Eye Epidemiology" (E3) consortium.

Authors:  Cécile Delcourt; Jean-François Korobelnik; Gabriëlle H S Buitendijk; Paul J Foster; Christopher J Hammond; Stefano Piermarocchi; Tunde Peto; Nomdo Jansonius; Alireza Mirshahi; Ruth E Hogg; Lionel Bretillon; Fotis Topouzis; Gabor Deak; Jakob Grauslund; Rebecca Broe; Eric H Souied; Catherine Creuzot-Garcher; José Sahel; Vincent Daien; Terho Lehtimäki; Hans-Werner Hense; Elena Prokofyeva; Konrad Oexle; Jugnoo S Rahi; Phillippa M Cumberland; Steffen Schmitz-Valckenberg; Sascha Fauser; Geir Bertelsen; Carel Hoyng; Arthur Bergen; Rufino Silva; Sebastian Wolf; Andrew Lotery; Usha Chakravarthy; Astrid Fletcher; Caroline C W Klaver
Journal:  Eur J Epidemiol       Date:  2015-12-19       Impact factor: 8.082

5.  Clinical differences between toric intraocular lens (IOL) and monofocal intraocular lens (IOL) implantation when myopia is determined as target refraction.

Authors:  Da Young Shin; Ho Sik Hwang; Hyun Seung Kim; Man Soo Kim; Eun Chul Kim
Journal:  BMC Ophthalmol       Date:  2021-05-08       Impact factor: 2.209

6.  The Montrachet Study: study design, methodology and analysis of visual acuity and refractive errors in an elderly population.

Authors:  Catherine Creuzot-Garcher; Christine Binquet; Sandrine Daniel; Lionel Bretillon; Nyiazi Acar; Aurélie de Lazzer; Laurent Arnould; Christophe Tzourio; Alain M Bron; Cécile Delcourt
Journal:  Acta Ophthalmol       Date:  2015-10-15       Impact factor: 3.761

7.  Unhealthy behaviours and risk of visual impairment: The CONSTANCES population-based cohort.

Authors:  Bénédicte M J Merle; Gwendoline Moreau; Anna Ozguler; Bernard Srour; Audrey Cougnard-Grégoire; Marcel Goldberg; Marie Zins; Cécile Delcourt
Journal:  Sci Rep       Date:  2018-04-26       Impact factor: 4.379

8.  Epiretinal Membrane Surgery in Daily Clinical Practice: Results of a Proposed Management Scheme.

Authors:  Jesús Pareja; Alba Coronado; Inés Contreras
Journal:  J Ophthalmol       Date:  2019-01-10       Impact factor: 1.909

9.  Ophthalmic Emergency Department Visits: Factors Associated With Loss to Follow-up.

Authors:  Evan M Chen; Aneesha Ahluwalia; Ravi Parikh; Kristen Nwanyanwu
Journal:  Am J Ophthalmol       Date:  2020-09-01       Impact factor: 5.258

10.  Outcome of 5-Year Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Using "Treat and Extend" Regimen.

Authors:  Polona Jaki Mekjavic; Polona Zaletel Benda
Journal:  Front Med (Lausanne)       Date:  2018-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.